Loading...

HRMY HARMONY BIOSCIENCES HOLDINGS INC Other Situations 8-K Filing

HRMN

HRMY

HARMONY BIOSCIENCES HOLDINGS INC

(HRMY)

2025 8-K

Financial Results Report

Trial Data Update

Financial Statements

Regulatory Compliance

Financial Statements

Board Appointment

Management Changes

Financial Results

Financial Results

Investor Day Announcement

Earnings Reports

Resignation and Name Change

Annual Meeting of Stockholders

Appointment of Chief Medica...

Financial Results Announcement

Sublicense Agreement

Financial Results Announcement

Earnings Report

Acquisition of Zynerba Phar...

Appointment of Director

Financial Results Announcement

Acquisition of Zynerba Phar...

Appointment of Officers

Generic Drug Filing

Credit Agreement Amendment

Merger Agreement

Financial Results Announcement

Entry into a Material Defin...

Financial Results Announcement

Appointment of CEO

Phase 3 INTUNE study on pit...

Financial Results Announcement

Management Changes

Management Changes

External Links:

On September 24, 2025, Harmony Biosciences Holdings, Inc. reported that its phase 3 trial, RECONNECT, did not meet its primary goal of improving social avoidance due to a high placebo response rate.

AI Assistant

HARMONY BIOSCIENCES HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.